Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Opthea stock

Learn how to easily invest in Opthea stock.

Opthea Ltd is a biotechnology business based in the US. Opthea shares (OPT) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Opthea

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OPT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Opthea stock price (NASDAQ: OPT)

Use our graph to track the performance of OPT stocks over time.

Opthea shares at a glance

Information last updated 2022-09-19.
Latest market close$5.94
52-week range$4.73 - $8.50
50-day moving average $6.62
200-day moving average $6.48
Wall St. target price$29.63
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.30

Buy Opthea shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Opthea stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Opthea price performance over time

Historical closes compared with the close of $5.94 from 2022-09-23

1 week (2022-09-19) -0.67%
1 month (2022-08-26) -5.26%
3 months (2022-06-24) -4.50%
6 months (2022-03-25) -7.19%
1 year (2021-09-24) -19.95%
2 years (2020-09-22) N/A
3 years (2019-09-22) N/A
5 years (2017-09-22) N/A

Opthea financials

Revenue TTM $199,005
Gross profit TTM $38,504
Return on assets TTM -60.81%
Return on equity TTM -101.29%
Profit margin 0%
Book value $1.09
Market capitalisation $271.8 million

TTM: trailing 12 months

Opthea share dividends

We're not expecting Opthea to pay a dividend over the next 12 months.

Have Opthea's shares ever split?

Opthea's shares were split on a 5:8 basis on 15 October 2020. So if you had owned 8 shares the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Opthea shares – just the quantity. However, indirectly, the new 60% higher share price could have impacted the market appetite for Opthea shares which in turn could have impacted Opthea's share price.

Opthea share price volatility

Over the last 12 months, Opthea's shares have ranged in value from as little as $4.7344 up to $8.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Opthea's is 0.4035. This would suggest that Opthea's shares are less volatile than average (for this exchange).

To put Opthea's beta into context you can compare it against those of similar companies.

Opthea overview

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. .

Frequently asked questions

What percentage of Opthea is owned by institutions?
Currently 25.238% of Opthea shares are held by institutions.
When does the fiscal year end for Opthea?
Opthea's fiscal year ends in June.
Where is Opthea based?
Opthea's address is: 650 Chapel Street, South Yarra, VIC, Australia, 3141
What is Opthea's ISIN number?
Opthea's international securities identification number is: US68386J2087

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site